| Literature DB >> 30596681 |
Huan Shu1,2, Christian H Lindh3, Sverre Wikström4, Carl-Gustaf Bornehag2,5.
Abstract
BACKGROUND: Perfluoroalkyl substances (PFAS) are used in numerous consumer products. They are persistent, bioaccumulating, and suspected to be endocrine disrupting chemicals (EDCs). A growing body of research has reported the association between PFAS exposure and adverse health effects. Concerns have been raised with special focus in childhood development.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30596681 PMCID: PMC6312341 DOI: 10.1371/journal.pone.0209255
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of the study population of 1,616 pregnant women in the SELMA study.
| 31(4.7) | |
| 2 (1–8) | |
| 4 (0–12) | |
| 88.2 | |
| 5.6 | |
| 6.1 | |
| 19.5 | |
| 46.0 | |
| 31.4 | |
| 3.0 |
Distribution of PFAS levels (ng/mL) in prenatal serum for 2,355 pregnant women in SELMA, and in a subgroup of 1,616 pregnant women that is the study population for the current report.
| Variable Name | Pregnant women in the entire SELMA study (N = 2,355) | ||||||
|---|---|---|---|---|---|---|---|
| N | LOD | Min | Median | 95th | Max | Geometric Mean | |
| PFNA | 2,355 | 0.01 | 0.06 | 0.52 | 1.30 | 8.70 | 0.53 (0.52–0.55) |
| PFDA | 2,355 | 0.02 | 0.03 | 0.25 | 0.61 | 4.00 | 0.26 (0.25–0.26) |
| PFUnDA | 2,345 | 0.02 | <LOD | 0.22 | 0.53 | 2.40 | 0.21 (0.20–0.21) |
| PFDoDA | 1,064 | 0.03 | <LOD | 0.03 | 0.08 | 0.39 | 0.026 (0.025–0.027) |
| PFHxS | 2,355 | 0.03 | 0.21 | 1.20 | 3.70 | 10.00 | 1.30 (1.28–1.34) |
| PFHpA | 1,716 | 0.01 | <LOD | 0.02 | 0.10 | 0.65 | 0.018 (0.017–0.019) |
| PFOA | 2,355 | 0.02 | 0.19 | 1.60 | 4.00 | 21.00 | 1.61 (1.57–1.64) |
| PFOS | 2,355 | 0.06 | 0.17 | 5.30 | 12.00 | 32.00 | 5.24 (5.13–5.36) |
Crude associations between three potential determinants (mothers age and smoking, fish intake, and parity) and PFAS in serum (N = 1,616).
| Correlation Coefficients (r) | ||||
|---|---|---|---|---|
| P-values | ||||
| PFAS | Age | Fish Intake Index | Parity | Smoking |
| -0.02 | -0.05 | |||
| 0.48 | 0.06 | |||
| 0.04 | ||||
| 0.11 | ||||
| -0.03 | 0.04 | |||
| 0.21 | 0.15 | |||
| -0.04 | 0.02 | -0.02 | ||
| 0.09 | 0.35 | 0.53 | ||
| 0.00 | 0.03 | |||
| 0.99 | 0.17 | |||
| -0.02 | 0.00 | |||
| 0.32 | 0.93 | |||
1) Log10 transformed
2) Pearson correlation
3) Spearman correlation
Crude serum levels (LSGM with 95% CIs) of PFAS (ng/mL) in each of four examined time periods and percentage change in LSGM with 2007 as a reference (N = 1,616).
| 2007 | 2008 | 2009 | 2010 | p-Value | ||
|---|---|---|---|---|---|---|
| %change (95%CI) | Reference | -3.5 | -7.0 | -8.8 | 0.30 | |
| LSGM (95%CI) | 0.57 (0.53–0.60) | 0.55 (0.53–0.58) | 0.53 (0.51–0.56) | 0.52 (0.47–0.58) | ||
| %change (95%CI) | Reference | -3.6 | -7.1 | -3.7 | 0.20 | |
| LSGM (95%CI) | 0.28 (0.26–0.29) | 0.27 (0.26–0.28) | 0.26 (0.25–0.27) | 0.27 (0.24–0.29) | ||
| %change (95%CI) | Reference | -4.5 | 0.0 | 13.6 | 0.15 | |
| LSGM (95%CI) | 0.22 (0.20–0.23) | 0.21 (0.20–0.22) | 0.22 (0.21–0.23) | 0.25 (0.22–0.28) | ||
| %change (95%CI) | Reference | -3.7 | 0.0 | 3.7 | 0.34 | |
| LSGM (95%CI) | 0.027 (0.025–0.029) | 0.026 (0.024–0.027) | 0.027 (0.026–0.029) | 0.028 (0.024–0.032) | ||
| %change (95%CI) | Reference | -6.5 | - | |||
| LSGM (95%CI) | 1.53 (1.43–1.64) | 1.43 (1.36–1.49) | 1.11 (1.06–1.16) | 1.33 (1.19–1.49) | ||
| %change (95%CI) | Reference | |||||
| LSGM (95%CI) | 0.022 (0.020–0.025) | 0.019 (0.017–0.020) | 0.017 (0.015–0.018) | 0.016 (0.013–0.020) | ||
| %change (95%CI) | Reference | -7.3 | ||||
| LSGM (95%CI) | 1.77 (1.65–1.89) | 1.64 (1.57–1.71) | 1.54 (1.48–1.61) | 1.49 (1.34–1.66) | ||
| %change (95%CI) | Reference | -6.5 | ||||
| LSGM (95%CI) | 6.2 (5.9–6.6) | 5.8 (5.6–6.1) | 4.7 (4.5–4.9) | 4.7 (4.5–5.1) |
*p<0.05
** p<0.01
*** p<0.001
Adjusted serum levels (LSGM with 95% CIs) of PFAS (ng/mL) in each of four examined time periods and percentage change in LSGM with 2007 as a reference (N = 1,616), adjusted for parity, mother age, smoking, and fish intakes.
| 2007 (n = 263) | 2008 (n = 654) | 2009 (n = 593) | 2010 (n = 106) | p-Value (overall) | ||
|---|---|---|---|---|---|---|
| %change | Reference | -4.1 | ||||
| LSGM (95%CI) | 0.58 (0.54–0.62) | 0.55 (0.53–0.58) | 0.53 (0.51–0.55) | 0.50 (0.45–0.55) | ||
| %change | Reference | -3.6 | -10.7 | |||
| LSGM (95%CI) | 0.28 (0.27–0.30) | 0.27 (0.26–0.28) | 0.25 (0.24–0.26) | 0.25 (0.23–0.28) | ||
| %change | Reference | -6.6 | -5.9 | 0.2 | 0.26 | |
| LSGM (95%CI) | 0.23 (0.21–0.24) | 0.21 (0.20–0.22) | 0.21 (0.20–0.22) | 0.23 (0.20–0.25) | ||
| %change | Reference | -7.3 | -2.9 | -4.7 | 0.36 | |
| LSGM (95%CI) | 0.028 (0.026–0.030) | 0.026 (0.025–0.027) | 0.027 (0.026–0.028) | 0.026 (0.023–0.030) | ||
| %change | Reference | -7.1 | ||||
| LSGM (95%CI) | 1.54 (1.43–1.64) | 1.43 (1.37–1.49) | 1.11 (1.06–1.16) | 1.30 (1.17–1.45) | ||
| %change | Reference | |||||
| LSGM (95%CI) | 0.023 (0.020–0.025) | 0.019 (0.017–0.020) | 0.017 (0.015–0.018) | 0.016 (0.013–0.019) | ||
| %change | Reference | |||||
| LSGM (95%CI) | 1.79 (1.69–1.91) | 1.64 (1.58–1.70) | 1.55 (1.48–1.61) | 1.42 (1.29–1.56) | ||
| %change | Reference | |||||
| LSGM (95%CI) | 6.4 (6.0–6.8) | 5.8 (5.6–6.1) | 4.7 (4.5–4.9) | 4.4 (4.0–4.8) |
*p<0.05
** p<0.01
*** p<0.001
Fig 1Time trends for serum levels (LSGM with 95% CIs) of PFAS (y-axis) during four periods from 2007 to 2010 (N = 1,616).
The model adjusted for parity, mother age, and fish intake in the family. *p<0.05 ** p<0.01*** p<0.001.